Literature DB >> 12602014

[Surgery of lung metastasis].

M D Delgado Muñoz1, J L Antón-Pacheco, J A Matute, J Cuadros, P Aguado, J L Vivanco, F J Berchi.   

Abstract

INTRODUCTION: The 30-40% of the oncologic patients have pulmonary metastases. Lung can be the only organ affected. In selected patients, exeresis of the pulmonary nodules can mean their healing.
MATERIAL AND METHODS: Between 1982-1997, twenty two patients presented metastases, 13 could be operated and 16 thoracotomies were done. There were 53% boys and 47% girls whose ages ranged from 3 to 15 years. We have considered: pulmonary tumour location, disease free interval, number of metastases, surgical technique and incomplete pulmonary tumour resection.
RESULTS: Primary tumours were: Wilms tumours 23%, bone tumours 67% (Ewing and osteosarcoma). Disease free interval was < 2 years in 8 patients (61%) and > 2 years in 39%. X-Ray and CT were performed in every case and 66% presented a solitary nodule. Surgical techniques were: metastasectomy in two cases (12%), wedge resection in 8 (50%) and lobectomy in six cases (38%). We made thoracoscopy in two patients. There weren't postoperatory mortality but the patients with tumorectomy had an incomplete surgical resection. The overall survival is 54 percent and the 5 years survival is 23 percent (3 patients).
CONCLUSIONS: The patients with a DFI < 2 years have a survival of 25% compared with 100% for patients who have a DFI > 2 years. The pulmonary resection in selected patients can offer better survival. We can use the thoracoscopy in same selected patients.

Entities:  

Mesh:

Year:  2000        PMID: 12602014

Source DB:  PubMed          Journal:  Cir Pediatr        ISSN: 0214-1221


  1 in total

1.  Thoracoscopic surgery in the management of pediatric malignancies: a multicentric survey of the Italian Society of Videosurgery in Infancy.

Authors:  C Esposito; M Lima; G Mattioli; L Mastroianni; G Riccipetitoni; G Monguzzi; G Zanon; G Cecchetto; A Settimi; V Jasonni
Journal:  Surg Endosc       Date:  2007-03-14       Impact factor: 3.453

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.